ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland and CFO Ian Griffiths discussed their transformative approach to cancer diagnostics through the company’s flagship technology, Parsortix at the Proactive One2One Forum.
Newland explained that Parsortix enables the precise separation of circulating tumour cells (CTCs) from blood samples, providing essential insights into cancer’s spread and helping guide targeted treatments.
This innovative approach bypasses traditional tissue biopsies, allowing doctors to perform repeat biopsies via blood samples, essential for tracking cancer's evolution. Newland went on to highlight that ANGLE is the only company with FDA clearance for use of this technology in capturing CTCs for analysis, setting it apart in the field.
The company’s partnerships with major pharmaceutical players like AstraZeneca and Eisai aim to integrate Parsortix with new drug development, potentially saving millions by refining patient selection for treatment trials. Emphasising that "we need companion diagnostics...that benefit the patient because they're more likely to get a drug which will be effective for them." The technology is already being used in over 100 peer-reviewed studies across 24 cancer types.
Looking ahead, ANGLE plans to further commercialise Parsortix in collaboration with pharmaceutical giants, solidifying its role in advancing personalised cancer treatment through high-sensitivity diagnostics.